Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Yet, their place and cost remain fairly misunderstood. For over a decade, Humira has been the highest-grossing drug in the world, bringing in some $21 billion for manufacturer AbbVie in 2021.
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
REITs pay dividends out of their funds from operations (FFO), and Vici's FFO per share is $2.61 over the last 12 months. This ...
Amjevita contains the active ingredient adalimumab-atto and is a biosimilar of the brand-name drug Humira (adalimumab). The “-atto” appears at the end of Amjevita’s name to show it’s ...
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...
All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.
9d
GlobalData on MSNBiosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.
The average tax refund in 2024 was $3,138, which was similar to the $3,167 it averaged the previous year. While tax refunds ...
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results